Background: The incidence of differentiated thyroid cancer (DTC) has rapidly increased 30 worldwide over the last decades. It is unknown if the increase in diagnosis has been mirrored 31 by an increase in thyroidectomy rates with the concomitant economic impact that this would 32 have on the healthcare system. 33 34 Methods: DTC and thyroidectomy incidence as well as DTC specific mortality were 35 modelled using Poisson regression in New South Wales (NSW), Australia per year and by 36 sex. The incidence of 2002 was the point from which the increase in rates were assessed 37 cumulatively over the subsequent decade. The economic burden of potentially avoidable 38 thyroidectomies due to the increase in diagnosis was estimated as the product of the 39 additional thyroidectomy procedures during a decade attributable to rates beyond those 40 reported for 2002 and the national average hospital cost of an uncomplicated thyroidectomy 41 in Australia.
Thyroid cancer cases, thyroidectomy procedures, and thyroid cancer specific 118 mortality in NSW were categorized by year of event (diagnosis or surgical procedure) and DTC incidence has increased to epidemic proportions worldwide over the last few 175 decades. Overdetection has not only increased DTC incidence, but it has also led to a 176 concurrent increase in thyroidectomy procedures with a huge economic burden on the 177 healthcare system (Table 2) . Over the last decade, we estimate that the number of potentially It should be emphasised that we base our conclusion regarding the lack of tangible 189 clinical gain only on the specific mortality rate having remained unchanged. There is, 190 however, no expectation that intervention may decrease morbidity that does not lead to death. 191 Unfortunately, these interventions themselves have been associated with morbidities. In fact, 192 paradoxically there is likely to be an increase in morbidity related to treatment if patients techniques and disease management) have to precisely mirror the increase in thyroid 207 incidence. Thus, improvements occurring at a faster or slower rate than changes in incidence 208 rate would certainly alter mortality rates and to assume an exact match between the rising 209 incidence and the improvements over 30 years is highly implausible. In a previous study, we 210 demonstrated that the reservoir of incidental DTC has remained stable since 1970 suggesting 211 that population level of tumorigenesis has remained unchanged (Furuya-Kanamori et al., 212 2016). Therefore, the most reasonable explanation for the rising thyroid cancer incidence 213 with stable mortality is that subclinical DTC is increasingly being detected due to the 214 improvements in diagnostic techniques, but these newly diagnosed subclinical cases may not 215 progress or will progress so slowly that the patient is more likely to die from other causes. process that should be adopted requires further evidence from prospective clinical studies, 253 and funding for such studies must be made a priority.
254
Our findings should be considered in the light of a few limitations. An important one 255 was the inability to conduct sub-group analyses by age group, patient ethnicity, tumour size, 256 and histopathology. However, we were able to stratify the analyses by sex, which is known to 257 be one of the strongest predictors of DTC incidence and thyroidectomy. We also make the 258 assumption based on our previous work that the rising trends are representative of that the rate of rise in thyroid cancer was observed across all tumour sizes. We agree with the 264 latter that the incidence of all sizes are rising but a re-analysis of our previous data 265 (Mankarios et al., 2014) stratified by tumour size and gender clearly demonstrates that the 266 rate of rise decreases with increasing size, though all sizes are increasingly detected (data not 267 shown). We believe that this again is consistent with overdiagnosis. Nevertheless, it is thus avoiding fears that clinicians may delay treatment and increase recurrent/persistent 274 disease within a selected sub-set of thyroid cancer patients with more aggressive disease.
275
In conclusion, the evidence base for avoidable costs to healthcare is clear and savings 276 expected are substantial from a conservative approach to both thyroid examination (only 277 when indicated) and management of thyroid cancer when detected. Current evidence suggests 278 that watchful waiting is a safe route for management of many of the latter patients if due 279 surveillance is properly managed. What remains to be mapped out is who exactly should be 280 offered active surveillance and the criteria for subsequent intervention. The incidence of thyroid cancer has increased worldwide 3-to 15-fold over the last decades. Overdetection has not only increased DTC incidence, but it has also led to a 179 concurrent increase in thyroidectomy procedures with a huge economic burden on the 180 healthcare system (Table 2) . Over the last decade, we estimate that the number of potentially 
F o r R e v i e w O n l y
1999 9·5 (9·3-9·7) - 0·5 (0·5-0·6) 3·2 (3·1-3·3) - 0·4 (0·3-0·4) 2000 10·1 (9·8-10·3) - 0·5 (0·5-0·6) 3·4 (3·2-3·5) - 0·4 (0·3-0·4) 2001 10·7 (10·4-10·9) - 0·5 (0·5-0·6) 3·6 (3·4-3·7) - 0·4 (0·3-0·4) 2002 11·3 (11·1-11·6) 9·1 (8·6-9·7) 0·5 (0·5-0·6) 3·8 (3·7-3·9) 3·0 (2·7-3·2) 0·4 (0·3-0·4) 2003 12·0 (11·8-12·3) 9·8 (9·3-10·3) 0·5 (0·5-0·6) 4·0 (3·9-4·2) 3·2 (2·9-3·4) 0·4 (0·3-0·4) 2004 12·8 (12·5-13·1) 10·5 (10·0-11·0) 0·5 (0·5-0·6) 4·3 (4·1-4·4) 3·4 (3·2-3·7) 0·4 (0·3-0·4) 2005 13·6 (13·3-13·9) 11·3 (10·8-11·8) 0·6 (0·5-0·6) 4·5 (4·4-4·7) 3·7 (3·4-3·9) 0·4 (0·3-0·4) 2006 14·4 (14·1-14·7) 12·1 (11·7-12·6) 0·6 (0·5-0·6) 4·8 (4·6-5·0) 3·9 (3·7-4·2) 0·4 (0·3-0·4) 2007 15·3 (14·9-15·6) 13·0 (12·6-13·5) 0·6 (0·5-0·6) 5·1 (4·9-5·3) 4·2 (4·0-4·5) 0·4 (0·3-0·4) 2008 16·2 (15·8-16·6) 14·0 (13·6-14·4) 0·6 (0·5-0·6) 5·4 (5·2-5·6) 4·5 (4·3-4·8) 0·4 (0·3-0·4) 2009 17·2 (16·7-17·7) 15·0 (14·6-15·5) 0·6 (0·5-0·6) 5·7 (5·5-6·0) 4·9 (4·6-5·2) 0·4 (0·3-0·4) 2010 18·2 (17·7-18·8) 16·2 (15·6-16·7) 0·6 (0·5-0·6) 6·1 (5·8-6·4) 5·2 (4·9-5·6) 0·4 (0·3-0·4) 2011 19·4 (18·8-19·9) 17·4 (16·7-18·0) 0·6 (0·5-0·7) 6·5 (6·2-6·8) 5·6 (5·3-6·0) 0·4 (0·3-0·4) 2012 20·5 (19·9-21·2) 18·6 (17·8-19·5) 0·6 (0·5-0·7) 6·9 (6·6-7·2) 6·0 (5·6-6·5) 0·4 (0·3-0·5)
191
It should be emphasised that we base our conclusion regarding the lack of tangible 192 clinical gain only on the specific mortality rate having remained unchanged., There is, 193 however, no expectation that intervention may decrease morbidity that does not lead to death. process that should be adopted requires further evidence from prospective clinical studies, 256 and funding for such studies must be made a priority.
257
Our findings should be considered in the light of a few limitations. An important one 258 was the inability to conduct sub-group analyses by age group, patient ethnicity, tumour size, 259 and histopathology. However, we were able to stratify the analyses by sex, which is known to 260 be one of the strongest predictors of DTC incidence and thyroidectomy. We also make the In conclusion, the evidence base for avoidable costs to healthcare is clear and savings 279 expected are substantial from a conservative approach to both thyroid examination (only 280 when indicated) and management of thyroid cancer when detected. Current evidence suggests 281 that watchful waiting is a safe route for management of many of the latter patients if due 282 surveillance is properly managed. What remains to be mapped out is who exactly should be 283 offered active surveillance and the criteria for subsequent intervention. 
